Acne is a disorder of the pilosebaceous unit, common among adolescents, which may be extended to adulthood. The aim of this study was to assess the prevalence of hormonal disorders in women with acne resistance to conventional therapy. We included 72 women aged between 15 and 36 years (divided in two age groups) who presented to our clinic between May and October 2014, suffering from moderate and severe forms of papulopustular and nodulocystic acne. The subjects were non-responsive to classic dermatological treatment or had clinical manifestation of hyperandrogenism. Based on age, we divided the women into two groups, group I with 40 patients aged 15–22years and group II with 32 patients aged 23–36 years. Using ELISA, a hormonal profile was performed for each patient in days 1–3 of the menstrual cycle including, total testosterone, dehydroepiandrosterone sulfate (DHEA-S), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, prolactin, and plasma cortisol. For statistical analysis we used Stata 13 software. We compared the hormonal profile of the two groups and identified significant differences for: testosterone levels (mean value, 0.64±0.35 vs. 0.97±0.50 ng/ml; p<0.0001), DHEA-S levels (mean value, 0.85±0.27 vs. 1.05±0.33 mg/24 h; p=0.001), prolactin levels (mean value, 281.85±91.113 vs. 353.969±102.841 mIU/ml; p=0.002) and LH levels (14.8±6.7 vs. 20.1±8.2 mIU/ml; p=0.002) were higher in group II. No statistically significant differences were found for estradiol (p=0.588) and cortisol (p=0.182) levels. In conclusion, refractory acne can be the first sign of systemic illness including polycystic ovary syndrome. Thus, for a correct therapeutic approach it is necessary to interpret the clinical and biochemical elements in correlation with the medical history.
Vulvovaginal candidiasis is the most prevalent vaginal infection worldwide. Considering the violence of the symptoms that some patients report, the tendency to relapse or of resistance to the azole therapy, and the success reported by some studies in the treatment with boric acid of the vaginal infection with various pathogens, we conducted a prospective study in which we used vaginal boric acid for Candida species infection. The aim of our study was to evaluate the effectiveness and tolerability of boric acid in the treatment of vaginal infection with Candida species. Analysing the data from the satisfaction questionnaire completed by the patients who reached the end of the study showed that our investigational product has a good and very good effectiveness in sterilizing the infection (71%), being considered by patients to be easily administered (67.7%), the safety of the product being perceived as good and very good by 93.6% of them.
Liposarcoma of the breast is a very rare soft tissue malignant tumor arising in the fat cells, with a prevalence of 0.3% of all malignant breast tumors, clinically manifested as a palpable breast mass mimicking a primary breast cancer. In the present paper, we had two objectives: (i) to report the first liposarcoma case in our Clinic and (ii) to screen the scientific literature on the topic. Our report presents an unusual case of a 56-year-old female with symptomatic left breast mass initially histopathologically diagnosed as a mesenchymal lesion. Four months later, the tumor was histopathologically identified as a grade 3 dedifferentiated liposarcoma (DDLPS) Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC; French Federation of Cancer Centers). We present the histopathological, immunohistochemical, and radiological features of the case and outcomes. Secondly, we performed a systematic search on liposarcoma on the PubMed ® /Medline ® and Web of Science ® databases, using the keyword "primary breast liposarcoma" (all-time topic). Due to the small number of cases found in the literature, the best treatment choice and determination of prognosis are difficult to make. Our patient underwent breast radical surgery, received adjuvant treatment, continuously monitored, being disease-free after five years of follow-up.
Many women spend a third of their lives in postmenopause, and it’s a given that sexual life must go on after menopause since its benefits were vastly proven. A number of factors influence sexuality in postmenopause: the age at which menopause sets in, how menopause sets in, physical and mental state, quality of sexual life in perimenopause and the quality and duration of the relationship with the partner. The hypoestrogenism that characterizes menopause leads to a decrease in libido, to changes in the genital apparatus (vaginal atrophy, dyspareunia) or other changes (hot flushes, impaired urination, depression), which negatively affect sexual health. Assessing sexual dysfunction is not easy. The interplay between the types of factors that predispose, precipitate and maintain sexual dysfunction requires preparation on the part of the clinician in identifying the elements of interest and indicating appropriate therapy. Research on the quantification of sexual dysfunction in women has led to the development of various scales or questionnaires to assess the impact of menopausal-related changes on sexual function and quality of intimate life. The ultimate goal of the clinician is to find an optimal method of treatment that will improve the condition and enhance the quality of sexual life. The available knowledge about menopausal sexuality may still be the tip of the iceberg in both medical practice and society and further research and information campaigns are greatly needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.